Evidence map›Paper›PMID 39859395›Full record

ArticleInternational journal of molecular sciences2025

An Immunocytochemistry Method to Investigate the Translationally Active HIV Reservoir.

Guoxin Wu, Samuel H Keller, Ryan T Walters, Yuan Li, Jan Kristoff, Brian C Magliaro, Paul Zuck, Tracy L Diamond, Jill W Maxwell, Carol Cheney and 5 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Guoxin WuMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.
Samuel H KellerMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.ORCID 0000-0001-9931-3266
Ryan T WaltersMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.
Yuan LiMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.
Jan KristoffMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.
Brian C MagliaroMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.
Paul ZuckMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.
Tracy L DiamondMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.ORCID 0000-0002-4672-8641
Jill W MaxwellMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.
Carol CheneyMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.
Qian HuangMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.
Carl J BalibarMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.ORCID 0000-0003-0854-4224
Thomas RushMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.
Bonnie J HowellMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.ORCID 0000-0002-5915-9943
Luca SardoMRL, Merck & Co., Inc., Rahway, NJ 07065, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the success of combination antiretroviral therapy (cART) to suppress HIV replication, HIV persists in a long-lived reservoir that can give rise to rebounding viremia upon cART cessation. The translationally active reservoir consists of HIV-infected cells that continue to produce viral proteins even in the presence of cART. These active reservoir cells are implicated in the resultant viremia upon cART cessation and likely contribute to chronic immune activation in people living with HIV (PLWH) on cART. Methodologies to quantify the active reservoir are needed. Here, an automated immunocytochemistry (ICC) assay coupled with computational image analysis to detect and quantify intracellular Gag capsid protein (CA) is described (CA-ICC). For this purpose, fixed cells were deposited on microscopy slides by the cytospin technique and stained with antibodies against CA by an automated stainer, followed by slide digitization. Nuclear staining was used to count the number of cells in the specimen, and the chromogenic signal was quantified to determine the percentage of CA-positive cells. In comparative analyses, digital ELISA, qPCR, and flow cytometry were used to validate CA-ICC. The specificity and sensitivity of CA-ICC were assessed by staining a cell line that expresses CA (MOLT IIIB) alongside a control cell line (Jurkat) devoid of this marker, as well as peripheral blood mononuclear cells (PBMCs) from HIV seronegative donors before or after ex vivo infection with an HIV laboratory strain. The sensitivity of CA-ICC was further assayed by spiking MOLT IIIB cells into uninfected Jurkat cells in limiting dilutions. In those analyses, CA-ICC could detect down to 10 CA-positive cells per million with a sensitivity superior to flow cytometry. To demonstrate the application of CA-ICC in pre-clinical research, bulk PBMCs obtained from mouse and non-human primate animal models were stained to detect HIV CA and SIV p27, respectively. The level of intracellular CA quantified by CA-ICC in PBMCs obtained from animal models was associated with plasma viral loads and cell-associated CA measured by qPCR and ELISA, respectively. The application of CA-ICC to evaluate the activity of small-molecule targeted activator of cell-kill (TACK) in clinical specimens is presented. Overall, CA-ICC offers a simple imaging method for specific and sensitive detection of CA-positive cells in bulk cell preparations.

Indexed as

HIV-1HIV InfectionsImmunohistochemistryAnimalsCapsid ProteinsHumansJurkat CellsMacaca mulattaMiceViral LoadVirus ReplicationCapsid ProteinsCA-ICCcapsid (CA)flow cytometryHIVimmunocytochemistry (ICC)p27qPCRSimoaSIVTACK

Identifiers

PMID39859395
PMCPMC11766174

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.